DrugBiological
Yttrium Y-90 ibritumomab tiuxetan clinical trials
Also written 90Y Ibritumomab tiuxetan.
A product of Ibritumomab tiuxetan; its studies count on that page too.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 1999
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2008 (3)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2001 | 1 |
| 2004 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 8
M.D. Anderson Cancer Center (1) · The Christie NHS Foundation Trust (1) · Lund University Hospital (1) · University of Alabama at Birmingham (1) · Stanford University (1) · National Cancer Institute (NCI) (1) · Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie (1) · Maisonneuve-Rosemont Hospital (1)
Often tested with
Tested in the same studies.
Rituximab (1) · Oprelvekin (1) · Interleukin-11 (1) · Filgrastim (1)
Studies
Open first, then newest update. How each study uses yttrium Y-90 ibritumomab tiuxetan is read from its arms, and is right about nine times in ten.
Testing it · 8
- Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)CompletedPhase 2M.D. Anderson Cancer CenterNCT01490723Written as 90Y IbritumomabTiuxetan
- Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular LymphomaCompletedPhase 2The Christie NHS Foundation TrustNCT01493479Written as 90Y Ibritumomab tiuxetan
- Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedPhase 1/2National Cancer Institute (NCI)NCT00012298Written as yttrium Y 90 ibritumomab tiuxetan
- High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell LymphomaCompletedPhase 1/2Lund University HospitalNCT00761384Written as 90Y-ibritumomab
- Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedPhase 2University of Alabama at BirminghamNCT00005592Written as 90-Y-ibritumomab tiuxetan
- Zevalin Twice in Aggressive Non-Hodgkin LymphomaTerminatedPhase 2Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle LeucemieNCT00902525Written as 90Y-Ibritumomab Tiuxetan
- 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHLCompletedPhase 1Stanford UniversityNCT00186589Written as 90Y Ibritumomab tiuxetan
- Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin LymphomaStatus unknownPhase 1/2Maisonneuve-Rosemont HospitalNCT00807196Written as 90Y ibritumomab tiuxetan (Zevalin)
Codes
What other systems call yttrium Y-90 ibritumomab tiuxetan · ClinicalTrials.gg INT017668
- NCI Thesaurus C1812Yttrium Y-90 Ibritumomab TiuxetanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| NCI Thesaurus | C1812 | Yttrium Y-90 Ibritumomab Tiuxetan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.